RNA Clinical Trials Articles

1. From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics 4/21/2026

   Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.

2. The RNA Ties That Bind: 3 Takeaways From The OPT Congress 4/1/2026

   Here, I unpack three takeaways I had from the OPT Congress, each of which I’d argue are indicative of the interconnectedness across the genetic medicines field.

3. How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation 3/19/2026

   Subtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.

4. 2026 RNA Investment Landscape: Recent Deals, IPOs, And Venture Trends 2/22/2026

   As RNA investing matures, capital is flowing toward delivery, durability, and regulatory credibility. This column breaks down the deals, IPO signals, and venture theses shaping RNA’s 2026 winners—and why.

5. A New Space Race: Reclaiming Efficiency In The mRNA Industry 1/27/2026

   It goes without saying that efficiency in drug development is tantamount — especially when it comes to getting much-needed clinical data. So, when I asked Allan Shaw about the ongoing trends he anticipates seeing more of in 2026, he immediately pointed to the increasing prominence of overseas development, particularly in nations like Australia and China. 

6. Money In The Bank: Why 2025's Setbacks Were The Foundation RNA Needed 1/5/2026

   I saw 2025 as a year that was foundational for our efforts to learn more about the biology and function of our products. However, there were two developments in particular that, to me, encapsulated the trials, tribulations, and ultimately the success of an industry that is doing its damnedest to answer one of the biggest questions facing us: “Why RNA?”  

7. Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026 12/16/2025

   Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond. 

8. Overcoming CMC Challenges In The Development Of Conjugated LNP Platforms For In Vivo CAR-T Therapy 11/4/2025

   Overcoming CMC hurdles is key to advancing conjugated LNP platforms for in vivo CAR-T therapy, enabling scalable, precise mRNA delivery to T cells while maintaining stability, potency, and regulatory compliance.

9. Beyond the Hype: Industry Experts on the Reality of mRNA in Cancer Care 10/31/2025

   When I asked a panel of experts at RNA Leaders why mRNA was best positioned to shine in oncology, I was met with a few expected talking points and — better yet — a few I wasn’t expecting. 

10. Tackling Challenges In RNA Stability And Organ Targeting 10/28/2025

    RNA therapeutics are reshaping medicine, but instability and limited organ targeting still pose challenges. Discover how next-gen lipid nanoparticles and smart delivery systems are advancing RNA precision.